Understanding anticoagulation therapy for stroke prevention and atrial fibrillation

  • Natalie Schellack University of Limpopo (Medunsa Campus)
  • Heleen Esterhuizen University of Limpopo (Medunsa Campus)
  • Gustav Schellack
Keywords: anticoagulation therapy, stroke, atrial fibrillation, warfarin, oral anticoagulants

Abstract

Atrial fibrillation (AF) is a common cardiac rhythm disorder and patients with this condition are at an increased risk of strokes and other thromboembolic events. Available treatment options for the prevention of strokes in patients with AF include warfarin, aspirin and the novel oral anticoagulants (NOACs). Warfarin and aspirin reduce the risk of strokes in patients with AF and have been studied extensively. The NOACs are slowly beginning to make their way onto the South African market and are specifically highlighted in this article.

Author Biographies

Natalie Schellack, University of Limpopo (Medunsa Campus)
BCur, BPharm, PhD (Pharmacy) Senior Lecturer Department of Pharmacy Faculty of Health Sciences University of Limpopo (Medunsa Campus)
Heleen Esterhuizen, University of Limpopo (Medunsa Campus)
BPharm Academic Intern Department of Pharmacy Faculty of Health Sciences University of Limpopo (Medunsa Campus)
Gustav Schellack
BCur, Hons BSc (Pharmacology) Clinical Team Manager Pharmaceutical Industry (Clinical Research)
Section
Reviews